What were the key takeaways from Coherus Oncology’s earnings call?

What does Coherus Oncology do and what are its main business segments?

What were the key takeaways from Coherus Oncology's earnings call?

What is the revenue and EPS growth rate for Coherus Oncology year over year?

Did Coherus Oncology beat or miss consensus estimates last quarter?

What is Coherus Oncology's gross profit margin?

What is the market's earnings forecast for Coherus Oncology next quarter?

What is Coherus Oncology's latest dividend and current dividend yield?

- **Revenue Surge**: LOQTORZI net revenue up 113% YoY to $40.8M in 2025, with Q4 demand growth of 15.5%.
- **Pipeline Momentum**: Tagmokitug and Casdozokitug trials across 8 tumor types, with first data mid-2026. J&J collaboration for prostate cancer combo.
- **Financial Strength**: $172M cash, 90% debt reduction, and 20% SG&A expense decline. Eligible for $75M in UDENYCA earn-outs.
- **Strategic Expansion**: Field force +15%, CRM tech doubling claims data coverage, targeting 65% of U.S. patients.

**【CEO Summary Section】**
- **Strategic Transformation**: Completed transition to an innovative oncology company focused on immune resistance, including the acquisition of Surface Oncology and divestiture of biosimilars, reducing debt from $480M to $38.8M.
- **LOQTORZI Growth**: 2025 net revenue of $40.8M (113% YoY growth), targeting $175M annualized by 2028. Q4 2025 demand growth of 15.5%, driven by new patient starts and guideline updates.
- **Pipeline Progress**: Tagmokitug (CCR8 Treg depleter) and Casdozokitug (IL-27 inhibitor) in clinical trials across multiple tumor types, with initial data expected mid-2026. J&J collaboration for Tagmokitug in prostate cancer announced.

**【CFO Financial Commentary】**
- **Financial Health**: $172.1M cash at year-end 2025, after raising $50M in Q1 2026. SG&A expenses reduced 20% YoY to $23.6M/Q4, while R&D increased 49% YoY to $31M/Q4.
- **Debt Reduction**: Principal debt reduced 90% since 2024, with no maturities until 2029. Interest costs saved >$15M YoY.
- **Earn-Out Milestones**: Eligible for $37.5M each for UDENYCA sales of $300M (by Q3 2026) and $350M (by Q1 2027).

**【Q&A Key Highlights】**
- **LOQTORZI Dynamics**: 25% of 2025 revenue from new patients; 10-15% QoQ demand growth expected. Expansion of field force and CRM tech to target 70% of U.S. claims data.
- **Tagmokitug Strategy**: Phase II CRC and J&J prostate cancer trials starting H2 2026. Focus on Treg depletion in combination therapies, with broad potential across modalities.
- **Competitive Landscape**: CCR8 field becoming competitive, with Tagmokitug's first-in-class status and J&J partnership providing differentiation.
- **R&D Spending**: Discretionary clinical trial costs managed; LOQTORZI sales expected to cover core burn by 2027, enabling pipeline investment.

Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript

**Key Takeaways**
- **Revenue Growth:** LOQTORZI Q3 revenue $11.2M (92% YoY), targeting $150-200M peak by 2028.
- **Pipeline Momentum:** 
  - CHS-114 Phase II trials in 4 solid tumors; Q1 2026 data expected.
  - Casdozokitug shows 38% ORR in HCC; Q1 2026 readouts.
- **Financial Strength:** $192M cash, 69% YoY liability reduction, <140 FTEs by year-end.
- **Commercial Expansion:** 15% sales force growth, digital campaigns to penetrate community oncologists.
- **Strategic Focus:** Treg depletion leadership; global partnerships to offset development costs.

**Core Details - Detail Page**

**CEO Opening Remarks**
- Reported strong financial progress: reduced expenses, strengthened balance sheet, and focus on pipeline drugs (LOQTORZI, CHS-114, casdozokitug).
- LOQTORZI: Revenue of $11.2M in Q3, 92% YoY growth, targeting $150-200M peak sales by mid-2028.
- Pipeline strategy: Global rights to CHS-114 and casdozokitug, pursuing partnerships for global development costs.

**CFO Financial Commentary**
- Q3 2025: Continuing operations net revenue $11.2M (LOQTORZI), 12% QoQ growth.
- R&D expenses: $27.3M (24% YoY increase), SG&A: $24.9M (11% YoY decrease).
- Cash and investments: $192M; liabilities reduced by 69% YoY.
- Headcount target: <140 FTEs by year-end.

**Pipeline Updates**
- **CHS-114 (CCR8 Treg depleter):** 
  - Phase II trials in head and neck, gastric, esophageal, and colorectal cancers.
  - Q3 2026 data expected for second-line head and neck, gastric, and colorectal cohorts.
  - Mechanism: Selective Treg depletion, CD8+ T cell infiltration, no off-target binding.
- **Casdozokitug (IL-27 antagonist):** 
  - Phase II in first-line HCC: 38% ORR, 17% CR vs. 30% ORR, 8% CR for atezolizumab.
  - Q1 2026 data expected for first-line HCC and second-line head and neck.
  - Mechanism: NK and T cell activation via IL-27 inhibition.

**Commercial Strategy**
- LOQTORZI: 15%+ QoQ demand growth in 3/4 regions; 15%+ account growth, 30% repeat use.
- Market focus: Community oncologists (1-2 NPC patients/year) via expanded sales force (+15%), remote teams, and digital campaigns.
- Long-term goal: 10-15% annual growth to achieve $150-200M NPC market share.

**Q&A Highlights**
- **R&D Strategy:** 
  - CHS-114 prioritization: Head and neck, gastric, colorectal (high CCR8+ Treg density).
  - Casdozokitug: First-line HCC, second-line head and neck.
- **Colorectal Trial:** 
  - Fourth-line MSS CRC: Mid-single-digit ORR benchmark; targeting durable responses.
  - Long-term plan: Earlier lines if successful.
- **Duration of Therapy:** 
  - LOQTORZI: Early launch phase; duration increasing but not yet at clinical trial levels.
  - Long-term goal: Align with clinical trial durability metrics.


Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call Transcript

- **LOQTORZI Growth Accelerates**: Q2 net revenue $10M (+36% Q/Q, +65% YoY), targeting $40M-$50M in 2025. Community oncologist adoption key to $150M-$200M NPC market dominance.
- **Pipeline Momentum**: CHS-114 Phase II data expected H1 2026; casdozokitug shows 38% ORR in HCC vs. 30% for standard of care. Strategic partnerships to expand indications cost-effectively.
- **Financial Strength**: $238M cash balance supports operations through 2026. FY2025 SG&A savings $30M YoY, positioning for efficient execution.
- **Strategic Differentiation**: LOQTORZI only approved PD-1 for NPC with Category 1 guidelines. Pipeline assets address $12B+ U.S. oncology markets.

**【CEO Summary Section】**
- Coherus Oncology repositioned as a focused oncology company with a pipeline of next-generation therapies. Key assets include toripalimab (LOQTORZI), CHS-114 (anti-CCR8), and casdozokitug (anti-IL-27). 
- LOQTORZI net revenue grew 36% Q/Q to $10M in Q2, driven by NPC adoption. Commercial focus on community oncologists to unlock $150M-$200M market opportunity.
- Pipeline strategy emphasizes combinations with external partners to cost-effectively expand LOQTORZI label and reduce development costs.

**【CMO and CSDO Clinical Updates】**
- **CHS-114 (anti-CCR8):** Phase II trials in head and neck, gastric, and esophageal cancers ongoing. Data expected H1 2026. Preclinical evidence shows Treg depletion and CD8+ T cell infiltration. No off-target binding, positioning as best-in-class.
- **Casdozokitug (anti-IL-27):** Phase II HCC trial (toripalimab + bevacizumab) shows 38% ORR vs. 30% for standard of care. Data expected H1 2026. Potential for combination with other modalities.
- **Toripalimab (LOQTORZI):** FDA-approved for NPC, with 37% OS improvement vs. chemo. Expansion opportunities in combination therapies and ex-U.S. partnerships.

**【Commercial Update】**
- LOQTORZI adoption in academic centers >90%, but community oncologists lag due to low patient volume. 2025 revenue target: $40M-$50M.
- Q2 2025 net revenue growth: 65% YoY. Community-focused initiatives include refreshed messaging, digital content, and real-time data targeting.
- Pipeline assets address large markets: HCC ($4B U.S.), head and neck ($4.5B), gastric ($3.5B), esophageal ($1B).

**【CFO Financial Commentary】**
- Q2 2025 cash balance: $238M, sufficient for runway through 2026. FY2025 SG&A guidance: $90M-$100M (down $30M YoY). R&D expenses dependent on clinical prioritization.
- Divestiture proceeds used to payoff $230M convertible notes and reduce UDENYCA royalty. FY2025 cash burn expected to moderate sequentially.
- Ex-U.S. licensing deals for pipeline assets expected to validate science, generate upfront payments, and offset development costs.

**【Q&A Highlights】**
- **Partnerships:** Actively seeking ex-U.S. partners for CHS-114 and casdozokitug. U.S. collaborations to expand LOQTORZI label cost-effectively.
- **Competitive Landscape:** CCR8 class under vigorous global development; no competitors with anti-IL-27 programs identified.
- **Community Adoption:** LOQTORZI penetration in community setting <50%. 3-4 year timeline to achieve peak sales due to dispersed patient volume.
- **Biosimilar Risk:** LOQTORZI is only FDA-approved PD-1 for NPC with Category 1 NCCN guidelines. No biosimilar competition anticipated.


Coherus BioSciences (CHRS)-7 Aug 25-2025 Q2 Earnings call transcript

- **LOQTORZI Dominance**: NPC market leadership with $150-200M annual revenue potential, driven by 15% Q1 demand growth and NCCN guideline preference.
- **Breakthrough Pipeline**: CHS-114 shows T-reg depletion and tumor shrinkage in head and neck cancer; casdozokitug achieves 17% CR in HCC trials.
- **Financial Resilience**: $200M net cash post-divestiture, $25M annual cost savings, and $90-100M SG&A guidance support R&D investment.
- **Strategic Expansion**: LOQTORZI partnerships reduce R&D costs, while CHS-114's CCR8 targeting opens $15M+ combination therapy opportunities.

**【CEO Summary Section】**
- **Innovative Oncology Focus**: Post-divestiture, Coherus is now a commercial-stage oncology company with LOQTORZI (toripalimab), the only FDA-approved PD-1 inhibitor for metastatic nasopharyngeal carcinoma (NPC). Revenue from NPC alone is projected to reach $150-200 million annually over three years.
- **Pipeline Expansion**: CHS-114 (CCR8 antibody) and casdozokitug (anti-IL-27) are advancing through clinical trials. CHS-114 showed T-reg depletion and tumor shrinkage in a Phase 1/2 trial, while casdozokitug achieved a 17% complete response rate in hepatocellular carcinoma (HCC) trials.
- **Strategic Partnerships**: Collaborations with Junshi Biologics and INOVIO are expanding LOQTORZI's indications, reducing R&D costs, and creating revenue synergies.

**【CFO Financial Commentary】**
- **Q1 2025 Results**: Continuing operations revenue was $7.3 million (LOQTORZI), with a 15% increase in patient demand. Discontinued operations (biosimilars) contributed $32.1 million, down 26% YoY due to UDENYCA divestiture.
- **Cost Savings**: $25 million annualized savings from headcount reductions, with full impact expected by year-end. SG&A for 2025 is projected at $90-100 million, excluding transaction costs.
- **Liquidity**: $483 million from UDENYCA sale, $170 million used to repurchase convertible notes, leaving $200 million net cash post-divestiture.

**【Q&A Key Themes】**
- **LOQTORZI Growth**: 15% Q1 demand growth driven by new accounts and repeat use. Sales force restructure in Q1 caused temporary headwinds, but Q2+ growth is expected to accelerate.
- **FDA Strategy**: Strong regulatory engagement (e.g., Type C meeting for CHS-114) ensures data-driven submissions. Experience navigating biosimilar approvals (e.g., pegfilgrastim) provides resilience against FDA changes.
- **Pipeline Momentum**: CHS-114 Phase 2 data expected H1 2026; Junshi's LOQTORZI + lenvatinib trial in HCC could yield pivotal results in 3-6 months.


Coherus BioSciences (CHRS)-12 May 25-2025 Q1 Earnings call transcript

- **$250M Post-Divestiture Cash**: UDENYCA sale completes strategic pivot to oncology, with 30% headcount reduction.
- **LOQTORZI Growth**: Q4 revenue up 29%, NCCN-preferred status driving 37% new patient starts.
- **Pipeline Breakthroughs**: Casdozokitug 38% ORR in HCC, CHS-114 47% disease stability in head & neck.
- **Sustainable Cash Runway**: 2+ years of liquidity to fund Phase III trials in NSCLC & gastric cancer.


**【CEO Strategic Overview】**
- Completed UDENYCA divestiture with $250M cash post-transaction, reducing headcount by 30% to 155 employees.
- LOQTORZI achieved $7.5M Q4 revenue, up 29% QoQ, with NCCN guidelines positioning as preferred treatment for metastatic NPC.
- Pipeline expansion: Casdozokitug in HCC shows 38% ORR (vs. 3-8% for competitors), CHS-114 CCR8 antibody in head & neck cancer shows 47% disease stability in heavily pretreated patients.

**【CFO Financial Highlights】**
- FY2024 UDENYCA net sales $206M (+62%), LOQTORZI $19.1M.
- COGS decreased $159M to $118M, driven by biosimilar divestitures.
- R&D/Sales & Admin expenses down 15%/13% to $93.3M/$167.7M, reflecting cost control.
- Cash runway exceeds 2 years post-divestiture, with $250M balance.

**【Commercial Execution】**
- UDENYCA Q4 sales $46.3M (+28%), market share 22% post-supply resumption.
- LOQTORZI new patient starts +37% QoQ, 80% of NCCN institutions using LOQTORZI.
- Price increase of 2.46% implemented for LOQTORZI.

**【Pipeline Progress】**
- Casdozokitug in HCC: 5 CRs (17%) vs. 3-8% for competitors, Phase III tori-bev-casdozo combo study ongoing.
- CHS-114 in head & neck: 47% disease stability, Phase Ib/II expansion for second-line gastric cancer opening Q2.
- Toripalimab approved in Europe for esophageal SCC, differentiated PD-1 with slow off-rate.

**【Q&A Key Takeaways】**
- Divestiture FDA clearance expected Q1, no remaining regulatory hurdles.
- LOQTORZI targeting $150-200M peak in NPC, 3-4 years to achieve 80% continuing patient share.
- Casdozokitug Phase III in NSCLC squamous cell likely 2026, against docetaxel standard-of-care.
- CCR8 intratumoral data: CD8 T-cell infiltration & Treg depletion key metrics for efficacy.


Actual												0.48	0.7	0.33	0.12	-2.37	-0.4	-0.49	-0.6	-1.24	-0.65	-1.11	-0.76	-0.96	-0.49	-0.41	-0.71	0.83	-0.11	-0.09	-0.44	-0.41	-0.39	-0.31	-0.39
Forecast												0.5151	0.2891	0.3661	0.2149	-0.2067	-0.21	-0.346	-0.46	-0.6467	-0.7838	-0.7169	-0.9815	-0.7213	-0.6289	-0.3903	-0.1988	-0.2536	-0.2487	-0.1634	-0.3056	-0.2974	-0.2203	-0.3539	-0.3551
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-6.81%	+142.13%	-9.86%	-44.16%	-1046.59%	-90.48%	-41.62%	-30.43%	-91.74%	+17.07%	-54.83%	+22.57%	-33.09%	+22.09%	-5.05%	-257.14%	+427.29%	+55.77%	+44.92%	-43.98%	-37.86%	-77.03%	+12.40%	-9.83%

Actual	--	--	--	--	--	--	--	--	--	--	--	116.18M	135.67M	113.55M	110.42M	83.03M	87.64M	82.50M	73.37M	60.12M	60.15M	45.42M	45.35M	32.40M	58.72M	74.57M	91.52M	77.06M	65.00M	70.77M	54.14M	7.60M	10.25M	11.57M	12.75M
Forecast	--	--	--	--	--	--	--	--	--	--	--	119.44M	102.52M	124.01M	114.89M	96.20M	87.04M	90.69M	82.61M	69.54M	62.04M	56.69M	47.69M	46.29M	50.47M	81.78M	96.89M	81.70M	62.06M	58.98M	44.15M	54.67M	9.35M	13.36M	13.91M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2.73%	+32.34%	-8.43%	-3.89%	-13.69%	+0.69%	-9.03%	-11.18%	-13.56%	-3.04%	-19.88%	-4.90%	-30.01%	+16.33%	-8.81%	-5.54%	-5.68%	+4.74%	+19.99%	+22.64%	-86.10%	+9.64%	-13.41%	-8.37%

CHRS

CHRS fundamentals

CHRS Q4 2025 Earnings

Earnings Call

You can ask Aime

CHRS

CHRS fundamentals

CHRS Q4 2025 Earnings

Earnings Call

CHRS Earnings Call Summary for Q4/20254:30 PM on Mar 9, 2026

CHRS Earnings Call Summary for Q3/20255:00 PM on Nov 6, 2025

CHRS Earnings Call Summary for Q2/20255:00 PM on Aug 7, 2025

CHRS Earnings Call Summary for Q1/20255:00 PM on May 12, 2025

CHRS Earnings Call Summary for Q4/20245:00 PM on Mar 10, 2025

You can ask Aime